233 related articles for article (PubMed ID: 31043611)
21. Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice.
DelBove J; Kuwahara Y; Mora-Blanco EL; Godfrey V; Funkhouser WK; Fletcher CD; Van Dyke T; Roberts CW; Weissman BE
Mol Carcinog; 2009 Dec; 48(12):1139-48. PubMed ID: 19676100
[TBL] [Abstract][Full Text] [Related]
22. Snf5 tumor suppressor couples chromatin remodeling, checkpoint control, and chromosomal stability.
Imbalzano AN; Jones SN
Cancer Cell; 2005 Apr; 7(4):294-5. PubMed ID: 15837618
[TBL] [Abstract][Full Text] [Related]
23. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability.
McKenna ES; Sansam CG; Cho YJ; Greulich H; Evans JA; Thom CS; Moreau LA; Biegel JA; Pomeroy SL; Roberts CW
Mol Cell Biol; 2008 Oct; 28(20):6223-33. PubMed ID: 18710953
[TBL] [Abstract][Full Text] [Related]
24. Loss of Snf5 Induces Formation of an Aberrant SWI/SNF Complex.
Sen P; Luo J; Hada A; Hailu SG; Dechassa ML; Persinger J; Brahma S; Paul S; Ranish J; Bartholomew B
Cell Rep; 2017 Feb; 18(9):2135-2147. PubMed ID: 28249160
[TBL] [Abstract][Full Text] [Related]
25. A Coil-to-Helix Transition Serves as a Binding Motif for hSNF5 and BAF155 Interaction.
Han J; Kim I; Park JH; Yun JH; Joo K; Kim T; Park GY; Ryu KS; Ko YJ; Mizutani K; Park SY; Seong RH; Lee J; Suh JY; Lee W
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32244797
[TBL] [Abstract][Full Text] [Related]
26. SMARCB1 loss induces druggable cyclin D1 deficiency via upregulation of MIR17HG in atypical teratoid rhabdoid tumors.
Xue Y; Zhu X; Meehan B; Venneti S; Martinez D; Morin G; Maïga RI; Chen H; Papadakis AI; Johnson RM; O'Sullivan MJ; Erdreich-Epstein A; Gotlieb WH; Park M; Judkins AR; Pelletier J; Foulkes WD; Rak J; Huang S
J Pathol; 2020 Sep; 252(1):77-87. PubMed ID: 32558936
[TBL] [Abstract][Full Text] [Related]
27. Chromatin remodeling: from transcription to cancer.
Yaniv M
Cancer Genet; 2014 Sep; 207(9):352-7. PubMed ID: 24825771
[TBL] [Abstract][Full Text] [Related]
28. Gene of the month: SMARCB1.
Kalimuthu SN; Chetty R
J Clin Pathol; 2016 Jun; 69(6):484-9. PubMed ID: 26941181
[TBL] [Abstract][Full Text] [Related]
29. SNF5 deficiency induces apoptosis resistance by repressing SATB1 expression in Sézary syndrome.
Li Y; Wang J; Yu M; Wang Y; Zhang H; Yin J; Li Z; Li T; Yan H; Li F; Wang X
Leuk Lymphoma; 2018 Oct; 59(10):2405-2413. PubMed ID: 29334836
[TBL] [Abstract][Full Text] [Related]
30. Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets.
Gadd S; Sredni ST; Huang CC; Perlman EJ;
Lab Invest; 2010 May; 90(5):724-38. PubMed ID: 20212451
[TBL] [Abstract][Full Text] [Related]
31. Tumor suppressor SMARCB1 suppresses super-enhancers to govern hESC lineage determination.
Langer LF; Ward JM; Archer TK
Elife; 2019 Apr; 8():. PubMed ID: 31033435
[TBL] [Abstract][Full Text] [Related]
32. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.
Nakayama RT; Pulice JL; Valencia AM; McBride MJ; McKenzie ZM; Gillespie MA; Ku WL; Teng M; Cui K; Williams RT; Cassel SH; Qing H; Widmer CJ; Demetri GD; Irizarry RA; Zhao K; Ranish JA; Kadoch C
Nat Genet; 2017 Nov; 49(11):1613-1623. PubMed ID: 28945250
[TBL] [Abstract][Full Text] [Related]
33. SMARCB1 Deficiency Integrates Epigenetic Signals to Oncogenic Gene Expression Program Maintenance in Human Acute Myeloid Leukemia.
Chatterjee SS; Biswas M; Boila LD; Banerjee D; Sengupta A
Mol Cancer Res; 2018 May; 16(5):791-804. PubMed ID: 29483235
[TBL] [Abstract][Full Text] [Related]
34. Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex.
Klochendler-Yeivin A; Picarsky E; Yaniv M
Mol Cell Biol; 2006 Apr; 26(7):2661-74. PubMed ID: 16537910
[TBL] [Abstract][Full Text] [Related]
35. Modulating the Expression Strength of the Baculovirus/Insect Cell Expression System: A Toolbox Applied to the Human Tumor Suppressor SMARCB1/SNF5.
Golas MM; Jayaprakash S; Le LTM; Zhao Z; Heras Huertas V; Jensen IS; Yuan J; Sander B
Mol Biotechnol; 2018 Nov; 60(11):820-832. PubMed ID: 30178299
[TBL] [Abstract][Full Text] [Related]
36. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic roles of SMARCB1/INI1 and its deficient tumors.
Kohashi K; Oda Y
Cancer Sci; 2017 Apr; 108(4):547-552. PubMed ID: 28109176
[TBL] [Abstract][Full Text] [Related]
38. NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition.
Drosos Y; Myers JA; Xu B; Mathias KM; Beane EC; Radko-Juettner S; Mobley RJ; Larsen ME; Piccioni F; Ma X; Low J; Hansen BS; Peters ST; Bhanu NV; Dhanda SK; Chen T; Upadhyaya SA; Pruett-Miller SM; Root DE; Garcia BA; Partridge JF; Roberts CWM
Mol Cell; 2022 Jul; 82(13):2472-2489.e8. PubMed ID: 35537449
[TBL] [Abstract][Full Text] [Related]
39. Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5.
Mora-Blanco EL; Mishina Y; Tillman EJ; Cho YJ; Thom CS; Pomeroy SL; Shao W; Roberts CW
Oncogene; 2014 Feb; 33(7):933-8. PubMed ID: 23435428
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation.
Erkek S; Johann PD; Finetti MA; Drosos Y; Chou HC; Zapatka M; Sturm D; Jones DTW; Korshunov A; Rhyzova M; Wolf S; Mallm JP; Beck K; Witt O; Kulozik AE; Frühwald MC; Northcott PA; Korbel JO; Lichter P; Eils R; Gajjar A; Roberts CWM; Williamson D; Hasselblatt M; Chavez L; Pfister SM; Kool M
Cancer Cell; 2019 Jan; 35(1):95-110.e8. PubMed ID: 30595504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
